Is Cosentyx Approved for All Psoriasis Types?
No, Cosentyx (secukinumab) is not approved or effective for all types of psoriasis. The FDA approves it specifically for moderate-to-severe plaque psoriasis in adults and children 6 years and older who are candidates for systemic therapy or phototherapy.[1] It targets IL-17A to reduce inflammation in plaque lesions, with clinical trials showing 80-90% of patients achieving PASI 75 (75% improvement) at week 12.[2]
How Does It Perform in Plaque Psoriasis Trials?
Pivotal trials like ERASURE and FIXTURE demonstrated high efficacy: 82% PASI 75 response with 300 mg dosing versus 4% placebo. Long-term data up to 5 years show sustained clearance in 70-80% of patients.[2] Real-world studies confirm similar results, though efficacy drops slightly in obese patients or those with prior biologic failures.
Why Isn't It Effective for Guttate or Pustular Psoriasis?
Cosentyx lacks FDA approval for non-plaque forms like guttate (sudden droplet-shaped lesions, often post-infection), pustular (pus-filled blisters), or erythrodermic (全身 red, peeling skin) psoriasis. Small studies show mixed results—some pustular cases respond, but relapses occur, and no large RCTs support routine use.[3] Guidelines (AAD/NPF) recommend it primarily for plaque, not these variants.
What About Psoriatic Arthritis with Skin Involvement?
Cosentyx is approved for active psoriatic arthritis (PsA) in adults and children 2 years+, covering skin symptoms alongside joint inflammation. In FUTURE trials, it improved skin clearance in 60-70% of PsA patients with plaque psoriasis.[1] This makes it suitable for overlap cases but not pure non-plaque psoriasis.
How Does Cosentyx Compare to Other Biologics Across Psoriasis Types?
| Psoriasis Type | Cosentyx Efficacy | Stronger Alternatives |
|---------------|------------------|----------------------|
| Plaque | High (PASI 90 in 60%) | Tremfya, Skyrizi (similar or slightly better skin clearance) |
| Guttate | Limited data, inconsistent | IL-23 inhibitors like Tremfya show better anecdotal response |
| Pustular | Off-label, variable; relapses common | Stelara or Spesolimab (IL-36 targeted, FDA-approved for generalized pustular) |
| Erythrodermic | Poor evidence; high risk of flare | Cyclosporine or infliximab preferred acutely |
Cosentyx underperforms in non-plaque due to IL-17's variable role versus IL-23 or IL-36 pathways in those forms.[4]
When Might It Fail Even in Plaque Psoriasis?
About 10-20% of plaque patients are primary non-responders, linked to high BMI, nail involvement, or anti-drug antibodies (develop in <5%).[2] Switching to IL-23 inhibitors like risankizumab often succeeds in these cases.
Patient Considerations and Access
Common side effects include upper respiratory infections (15%) and candidiasis (3-5%), higher than some competitors.[1] No patent data directly impacts efficacy, but generics/biosimilars are years away (key patents expire 2032-2034).[5] Consult a dermatologist for type-specific testing before starting.
[1]: FDA Label - Cosentyx (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125504s042lbl.pdf)
[2]: NEJM - Secukinumab Phase 3 Trials (https://www.nejm.org/doi/full/10.1056/NEJMoa1314258)
[3]: JAAD - IL-17 in Pustular Psoriasis Review (https://www.jaad.org/article/S0190-9622(20)32345-6/fulltext)
[4]: Lancet - Psoriasis Heterogeneity (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30985-7/fulltext)
[5]: DrugPatentWatch - Cosentyx Patents (https://www.drugpatentwatch.com/p/tradename/COSENTYX)